Customer No. 28880

Approved to

"OFFICIAL"

U.S. Patent and Trademark Office Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it displays a valid OMB control number. TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING Docket Number (Optional) PC10491A REJECTION OVER A PRIOR PATENT In re Application of: Mark C. Noc, et al. Application No.: 09/635,433 Filed: August 10, 2000 For: SELECTIVE INHIBITION OF AGGRECANASE IN OSTEOARTHRITIS TREATMENT percent interest in the instant application hereby Pfizer Inc. disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as presently __. The owner hereby agrees that any patent shortened by any terminal disclaimer, of prior Patent No. _ 6.329.397 so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal Check either box 1 or 2 below, if appropriate. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. The undersigned is an attorney or agent of record. Todd M. Crissey Typed or printed name 734-622-7813 Telephone Number Terminal disclaimer fee under 37 CFR 1.20(d) included. (Authorization for Deposit Account on Fce Sheet) WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. *Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).

Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 97 GFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the public whi

PAGE 5/19* RCVD AT 5/12/2004 4:47:19 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/6* DNIS:8729306 * CSID: * DURATION (mm-ss):05-40

Form PTO/SB/96 may be used for making this certification. See MPEP § 324.